FOR EIGHT CONSECUTIVE YEARS! HANSOH PHARMA MAINTAINS IN THE TOP THREE OF "BEST INDUSTRIAL ENTERPRISE FOR PHARMACEUTICAL R&D PRODUCT LINE IN CHINA"
From September 6th to 9th, the 41st China Pharmaceutical Industry Information Annual Conference was held in Chengdu, where the highly anticipated rankings for the Top 100 Chinese Pharmaceutical Industries, along with a series of special rankings, were ceremoniously released by the Ministry of Industry and Information Technology. Hansoh Pharma's chief subsidiary, Jiangsu Hansoh Pharma, has been ranked among the Top 100 Chinese Pharmaceutical Industries. Boasting outstanding innovative achievements and exceptional comprehensive competitiveness, it ranked among the top three in the "Best Industrial Enterprise for Pharmaceutical R&D Product Line in China" for eight consecutive years.
The "Best Industrial Enterprise for Pharmaceutical R&D Product Line in China” is one of the most authoritative and representative industry ranking events in China. The list is meticulously curated by a professional panel based on objective data and research analysis. Amid significant changes in the pharmaceutical industry in China and worldwide, the companies on the list have shown remarkable resilience in their innovative development.
In the first half of 2024, Hansoh Pharma's R&D expenditure reached approximately 1.196 billion RMB, representing a record high year-on-year increase of around 28.7%. Currently, the company has established R&D centers in Maryland in the United States as well as in Shanghai, Changzhou, and Lianyungang in China, which altogether are supported by over 1700 professional research staff. To further establish a hub for cutting-edge scientific innovation and a leading center for technology, Hansoh Pharma began the construction of its global R&D headquarter in Shanghai in March 2024, spanning over 90,000 square meters.
Driven by both independent research and external collaborations, Hansoh Pharma is dedicated to addressing unmet clinical needs. By leveraging advanced international technology platforms such as ADCs, monoclonal antibodies, bispecific antibodies, siRNA, and fusion proteins, the company is strengthening its presence in oncology while expanding into fields such as anti-infection, central nervous system disorders, metabolic diseases, and autoimmune conditions. Currently, Hansoh Pharma has over 30 innovative drugs in more than 50 clinical trials.
"Innovation + internationalization" has become the new drivers of sustainable growth for Hansoh Pharma. While maintaining a strong focus on independent research and development, the company has established 11 collaborative projects and successfully licensed global rights for two of its self-developed ADC products to leading international pharmaceutical companies. This strategy is designed to accelerate the translation of research outcomes and benefit patients both in China and worldwide.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
